Fig. 7
From: Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells
Targeting MAGEA3 increased the efficacy of cytotoxic/genotoxic agents in vitro. a Cystal violet stained images of the plates and the corresponding quantification bar graph for indicated conditions showing reduced viability of MAGEA3 depleted cells. The values represent percentage viability calculated using the formulae A540nm (treated)/A540nm (Untreated, Csi) X 100, Mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.005 and *** = p < 0.001, n = 3. b Bright field micrographs (scale bar = 100 μm) showing reduced number of healthy cells (intact cell membrane and attached to culture plate) in MAGEA3 depleted condition in response to indicated compounds. c, d Cell viability assay (MTT assay graph; c and FACS analysis, showing both annexinV negative and propidium iodide negative cell population; d) shows decreased viable cells in MAGEA3 depleted condition in response to indicated molecules/agents (after 72 h siRNA and after 48 h drug treatment). The values presented in graph are Mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.005, *** = p < 0.001. e MTT assay showing ectopic expression of MAGEA3 gives survival advantage to cancer cells in presence of various cytotoxic drugs (48 h drug treatment). The values presented in graph are Mean ± SEM, n = 3. * = p < 0.05. f Immunoblot showing increased apoptotic cell marker cleaved caspase3 upon MAGEA3 depletion in BxPC3 cells and the same is decreased upon ectopic expression of MAGEA3 in MiaPaCa2 cells at indicated conditions. 5FU, 5-Fluorouracil; DOXO, Doxorubicin, GEM, Gemcitabine